Difference between revisions of "Cixutumumab (IMC-A12)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Intravenous chemotherapy" to "Category:Intravenous medications") |
Warner-admin (talk | contribs) m (Text replacement - "[http://www.ncbi" to "[https://www.ncbi") |
||
| (18 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
Monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R). | Monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R). | ||
| − | =Preliminary data= | + | ==Preliminary data== |
| − | ==[[ | + | ===[[Adrenocortical carcinoma]]=== |
| − | # Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA, Phan AT, Habra MA, Kurzrock R. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer. 2013 Mar 5;108(4):826-30. Epub 2013 Feb 14. [https://www.ncbi.nlm.nih.gov/pubmed/23412108 PubMed] | + | # Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA, Phan AT, Habra MA, Kurzrock R. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer. 2013 Mar 5;108(4):826-30. Epub 2013 Feb 14. [https://doi.org/10.1038/bjc.2013.46 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590681/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23412108/ PubMed] |
| − | ==[[ | + | ===[[Ewing sarcoma]]=== |
| − | # Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA, Kurzrock R. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res. 2012 May 1;18(9):2625-31. Epub 2012 Mar 31. [https://www.ncbi.nlm.nih.gov/pubmed/22465830 PubMed] | + | # Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA, Kurzrock R. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res. 2012 May 1;18(9):2625-31. Epub 2012 Mar 31. [https://doi.org/10.1158/1078-0432.ccr-12-0061 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875297/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/22465830/ PubMed] |
| − | ==[[ | + | ===[[Soft tissue sarcoma]]=== |
| − | # Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adkins D, Van Tine BA, Brockstein B, Yim V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RG. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013 Apr;14(4):371-82. Epub 2013 Mar 8. [https://www.ncbi.nlm.nih.gov/pubmed/23477833 PubMed] | + | # '''NCI-2011-01408:''' Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adkins D, Van Tine BA, Brockstein B, Yim V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RG. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013 Apr;14(4):371-82. Epub 2013 Mar 8. [https://doi.org/10.1016/s1470-2045(13)70049-4 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3766955/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23477833/ PubMed] [https://clinicaltrials.gov/study/NCT01016015 NCT01016015] |
| − | ==[[Thymoma]]== | + | ===[[Thymoma]]=== |
| − | # Rajan A, Carter CA, Berman A, Cao L, Kelly RJ, Thomas A, Khozin S, Chavez AL, Bergagnini I, Scepura B, Szabo E, Lee MJ, Trepel JB, Browne SK, Rosen LB, Yu Y, Steinberg SM, Chen HX, Riely GJ, Giaccone G. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2014 Feb;15(2):191-200. Epub 2014 Jan 15. [https://www.ncbi.nlm.nih.gov/pubmed/24439931 PubMed] | + | # '''NCI 09-C-0212:''' Rajan A, Carter CA, Berman A, Cao L, Kelly RJ, Thomas A, Khozin S, Chavez AL, Bergagnini I, Scepura B, Szabo E, Lee MJ, Trepel JB, Browne SK, Rosen LB, Yu Y, Steinberg SM, Chen HX, Riely GJ, Giaccone G. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2014 Feb;15(2):191-200. Epub 2014 Jan 15. [https://doi.org/10.1016/s1470-2045(13)70596-5 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3954701/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24439931/ PubMed] |
| − | + | ==Also known as== | |
| − | [[Category: | + | *'''Code name:''' IMC-A12 |
| + | |||
| + | [[Category:Drugs]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | + | ||
[[Category:Anti-IGF-1R antibodies]] | [[Category:Anti-IGF-1R antibodies]] | ||
| − | [[Category: | + | [[Category:Adrenocortical carcinoma medications (investigational)]] |
| − | [[Category: | + | [[Category:Osteosarcoma medications (investigational)]] |
| − | [[Category: | + | [[Category:Soft tissue sarcoma medications (investigational)]] |
| − | [[Category:Thymoma medications]] | + | [[Category:Thymoma medications (investigational)]] |
| − | [[Category:Investigational]] | + | [[Category:Investigational drugs]] |
Latest revision as of 23:51, 6 July 2024
Mechanism of action
Monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R).
Preliminary data
Adrenocortical carcinoma
- Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA, Phan AT, Habra MA, Kurzrock R. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer. 2013 Mar 5;108(4):826-30. Epub 2013 Feb 14. link to original article link to PMC article PubMed
Ewing sarcoma
- Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA, Kurzrock R. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res. 2012 May 1;18(9):2625-31. Epub 2012 Mar 31. link to original article link to PMC article PubMed
Soft tissue sarcoma
- NCI-2011-01408: Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adkins D, Van Tine BA, Brockstein B, Yim V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RG. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013 Apr;14(4):371-82. Epub 2013 Mar 8. link to original article link to PMC article PubMed NCT01016015
Thymoma
- NCI 09-C-0212: Rajan A, Carter CA, Berman A, Cao L, Kelly RJ, Thomas A, Khozin S, Chavez AL, Bergagnini I, Scepura B, Szabo E, Lee MJ, Trepel JB, Browne SK, Rosen LB, Yu Y, Steinberg SM, Chen HX, Riely GJ, Giaccone G. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2014 Feb;15(2):191-200. Epub 2014 Jan 15. link to original article link to PMC article PubMed
Also known as
- Code name: IMC-A12